Machine Learning Modeling of Cancer Treatment-Related Cardiac Events in Breast Cancer: Utilizing Dosiomics and Radiomics
dc.authorscopusid | 59331562000 | |
dc.authorscopusid | 6603614581 | |
dc.authorscopusid | 25631592800 | |
dc.contributor.author | Dinçer, Şefika | |
dc.contributor.author | Akmansu, Müge | |
dc.contributor.author | Akyol, Oya | |
dc.date.accessioned | 2025-09-30T16:35:30Z | |
dc.date.available | 2025-09-30T16:35:30Z | |
dc.date.issued | 2025 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | [Dinçer] Şefika, Department of Radiation Oncology, Van Yüzüncü Yıl Üniversitesi, Van, Turkey; [Akmansu] Müge, Department of Radiation Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey; [Akyol] Oya, Department of Radiation Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey | en_US |
dc.description.abstract | Background: Personalized medicine has transformed disease management by focusing on individual characteristics, driven by advancements in genome mapping and biomarker discoveries. Objectives: This study aims to develop a predictive model for the early detection of treatment-related cardiac side effects in breast cancer patients by integrating clinical data, high-sensitivity Troponin-T (hs-TropT), radiomics, and dosiomics. The ultimate goal is to identify subclinical cardiotoxicity before clinical symptoms manifest, enabling personalized surveillance strategies. It is the first study to utilize heart-segmented dosiomics in breast cancer patients. Methods and Materials: This retrospective study included clinical, dosimetric, radiomic, and dosiomic data from 42 women with localized breast cancer. Heart-specific Troponin T levels were measured 2–3 weeks post-radiotherapy, with 14 ng/L as the cutoff. Patients were grouped on this threshold to identify potential treatment-related cardiac events. Radiomics and dosiomics were extracted using PyRadiomics. Machine learning models were optimized using the Tree-based Pipeline Optimization Tool (TPOT), identifying the gradient-boosted classification as the best-performing algorithm. Feature selection was conducted using gradient-boosted recursive feature elimination. Model performance is assessed by the area under the curve (AUC). Results: A total of 111 dosiomic and 119 radiomic features were extracted per patient. The highest predictive accuracy was achieved using clinical, dosiomic, and radiomic parameters (validation cohort-AUC = 0.96), outperforming the clinical + dosimetric model (validation cohort-AUC = 0.67). Permutation tests confirmed the non-randomness of these two models results (p <0.05). Cross-validation indicated that the clinical + dosiomic + radiomic model had a fair-to-good generalizable performance (mean AUC = 80.33 ± 21%). Discussion: This study may demonstrate that radiomics and dosiomics provide superior predictive capabilities for cardiac events in breast cancer patients compared to traditional parameters. © 2025 Elsevier B.V., All rights reserved. | en_US |
dc.identifier.doi | 10.3389/fonc.2025.1557382 | |
dc.identifier.scopus | 2-s2.0-105014873726 | |
dc.identifier.scopusquality | N/A | |
dc.identifier.uri | https://doi.org/10.3389/fonc.2025.1557382 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14720/28572 | |
dc.identifier.volume | 15 | en_US |
dc.identifier.wosquality | N/A | |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Media SA | en_US |
dc.relation.ispartof | Frontiers in Oncology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Dosiomics | en_US |
dc.subject | Machine Learning | en_US |
dc.subject | Oncologic Treatment-Related Cardiotoxicity | en_US |
dc.subject | Onco-Cardiology | en_US |
dc.subject | Radiomics | en_US |
dc.subject | Troponin T | en_US |
dc.subject | Area Under the Curve | en_US |
dc.subject | Article | en_US |
dc.subject | Breast Cancer | en_US |
dc.subject | Cancer Patient | en_US |
dc.subject | Cancer Radiotherapy | en_US |
dc.subject | Cancer Staging | en_US |
dc.subject | Cancer Therapy | en_US |
dc.subject | Cardiology | en_US |
dc.subject | Cardiotoxicity | en_US |
dc.subject | Cardiovascular Disease | en_US |
dc.subject | Cohort Analysis | en_US |
dc.subject | Computer-Assisted Tomography | en_US |
dc.subject | Dosimetry | en_US |
dc.subject | Early Cancer Diagnosis | en_US |
dc.subject | Female | en_US |
dc.subject | Human | en_US |
dc.subject | Intensity-Modulated Radiation Therapy | en_US |
dc.subject | Oncology | en_US |
dc.subject | Prediction | en_US |
dc.subject | Predictive Model | en_US |
dc.subject | Radiation Dose | en_US |
dc.subject | Random Forest | en_US |
dc.subject | Retrospective Study | en_US |
dc.subject | Support Vector Machine | en_US |
dc.title | Machine Learning Modeling of Cancer Treatment-Related Cardiac Events in Breast Cancer: Utilizing Dosiomics and Radiomics | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication |